The decision isn’t arbitrary, it’s built on three things mainly, what the tumor’s specific biomarkers show, how aggressive the cancer is behaving, and how quickly it actually needs to be brought under control. A tumor with strong markers for immunotherapy response, high PD-L1 expression for instance, might do well with immunotherapy alone. A more aggressive cancer, or one that needs a faster response, often gets the combination instead, since chemotherapy can start working while immunotherapy takes time to ramp up.
Dr. Sandeep Nayak, known for the Best Cancer Treatment in Bangalore, makes this call based on lab results more than instinct. “Patients sometimes assume immunotherapy alone is the gentler, better option and chemotherapy is what you use if that doesn’t work. It’s not that simple. Some tumors respond beautifully to immunotherapy by itself. Others need chemotherapy in the mix from day one because the biology and the timeline demand it. The biomarker testing tells us which situation we’re actually in.”
Curious which approach fits your specific diagnosis?
What Actually Decides Between the Two?
|
Factor |
Immunotherapy Alone |
With Chemotherapy |
|
Biomarkers |
High PD-L1 may favor it |
Lower or unclear markers may favor combination |
|
Cancer behavior |
Less aggressive disease |
Fast-growing or advanced disease |
|
Response |
May take longer |
Can act faster |
|
Patient health |
Useful when avoiding chemo is important |
Depends on chemo tolerance |
Overall patient health and tolerance for chemotherapy’s side effects also matter, since the two treatments affect the body very differently. Read more about immunotherapy vs chemotherapy side effects
What This Actually Means for Treatment and Side Effects?
- Immunotherapy and chemotherapy can cause different side effects. Hair loss and low blood counts are usually less common with immunotherapy.
- Using both treatments can mean dealing with side effects from both.
- Chemotherapy can sometimes work faster, while immunotherapy may take longer to show a response.
- Regular scans and blood tests help doctors see whether the treatment is working and if anything needs to be changed.
The best option depends on the type of cancer, the treatment plan, and how well the patient tolerates the treatment.
Why Choose MACS Clinic for Personalized Treatment Planning?
Dr. Sandeep Nayak’s team runs the biomarker testing that actually informs this decision as part of precision oncology planning, rather than defaulting to a standard combination regardless of what the tumor’s biology actually shows. That testing happens before treatment starts, not after the first option stops working, so the initial recommendation is already built around what that specific tumor is likely to respond to. If the disease shifts along the way, the plan gets reassessed against fresh imaging and markers rather than sticking to the original approach out of habit.
Want to understand which approach fits your own diagnosis? Reach the team at +91 9482202240.
FAQs
Can treatment switch from immunotherapy alone to the combination later if needed?
Yes, this happens fairly often. If immunotherapy alone isn’t producing the expected response, chemotherapy can be added based on how the disease is progressing.
Does combination treatment always work better than immunotherapy alone?
Not universally. For tumors with strong biomarker profiles favoring immunotherapy, adding chemotherapy doesn’t always improve outcomes and can add unnecessary side effects.
How is the biomarker testing itself done?
Usually through tissue from a biopsy sample, tested for markers like PD-L1 expression, sometimes alongside broader genomic testing depending on the cancer type.
Is one approach considered the standard starting point for most cancers?
No, it varies significantly by cancer type. What’s standard for lung cancer can look completely different from what’s standard for melanoma or bladder cancer
Reference Links
PubMed – Updated TOPAZ-1 results
PubMed – 4-year TOPAZ-1 analysis
Disclaimer:This content is published for educational and informational purposes only.